Press releases

New devices combine longest-lasting battery technology, therapy optimization and HeartLogic™ heart failure diagnostics

Late-breaking clinical trials feature subcutaneous implantable defibrillator (S-ICD) and WATCHMAN™ left atrial appendage closure device

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2017 Healthcare Conference on Thursday, May 18, 2017 in Las Vegas. Susie Lisa, vice...

"We are pleased with our performance in the first quarter,” said CEO Mike Mahoney

MADIT S-ICD trial to study EMBLEM™ MRI S-ICD System; part of pilot initiative to increase percentage of females enrolled in clinical studies

Boston Scientific will webcast both its Investor Day meeting and its conference call with financial results for Q1 ended March 31, 2017. Learn how to tune in.

Acquisition will expand treatments for patients with valvular heart disease and strengthen company's position in structural heart globally

Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; potential for significant cost savings

Edwards found to infringe on Boston Scientific patents in Germany and U.K.

Boston Scientific will participate in the healthcare conference on March 15, 2017. A live webcast and replay will be available.